ASCO 2021 | Surgical endpoints are needed in lung cancer trials of neoadjuvant therapy

Jonathan Spicer, MD, PhD, McGill University, Montreal, Canada, highlights the importance of introducing new endpoints in clinical trials of neoadjuvant approaches for lung cancer. Assessment of the impact of neoadjuvant therapy on surgical outcomes is an important factor to consider in this growing field. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.